Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene in AML and MDS
NCT02807558Phase 2Completed
- Sponsor
- Syros Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of tamibarotene in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Syros Pharmaceuticals. Started Sep 2016; status: completed.
02
Drugs
tamibarotene
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02807558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807558.